Alto Neuroscience, Inc. (NYSE: ANRO) Targets Significant Growth in Neuropsychiatric Treatment

Font: Financial Modeling Prep  • Mar 16, 2026

• Jefferies analyst Andrew Tsai sets a price target of $35 for NYSE:ANRO, indicating a potential upside of 41.24%.
• Alto Neuroscience secures approximately $120 million through private placement financing to advance its neuropsychiatric treatment pipeline.
• The stock's performance reflects strong investor interest with a notable increase of 9.75%, reaching a year-high of $24.94.

Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders. The company aims to address unmet needs in mental health treatment through innovative therapies. As of March 16, 2026, Andrew Tsai from Jefferies set a price target of $35 for ANRO, suggesting a potential upside of 41.24% from its trading price of $24.78.

Recently, Alto Neuroscience announced a significant financial milestone by securing approximately $120 million through a private placement financing. This capital injection is expected to support the company's efforts in advancing its pipeline of treatments for neuropsychiatric conditions. The influx of funds is crucial for the development and potential commercialization of their innovative therapies.

ANRO's stock is currently priced at $24.43, reflecting a notable increase of 9.75% with a change of $2.17. The stock's performance today saw a low of $21.76 and a high of $24.94, which is also its highest price over the past year. This indicates strong investor interest and confidence in the company's future prospects.

The stock's market capitalization stands at approximately $759 million, with a trading volume of 512,010 shares. This level of market activity suggests that investors are actively engaging with the stock, likely influenced by the recent financial developments and the positive outlook provided by Jefferies' price target.

Alto Neuroscience's lowest stock price over the past year was $1.60, highlighting the significant growth it has experienced. The company's focus on precision medicines for neuropsychiatric disorders, combined with the recent financial boost, positions it well for continued progress in its field.